

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER 2017

(₹ In Lakhs)

Sr. No	Particulars	Quarter ended 31.12.2017 (Unaudited)	Quarter ended 30.09.2017 (Unaudited)	Quarter ended 31.12.2016 (Unaudited)	Nine months ended 31.12.2017 (Unaudited)	Nine months ended 31.12.2016 (Unaudited)	Year ended 31.03.2017 (Audited)
1	Income from Operations						
	(a) Revenue from Operations	27,419	28,004	27,221	75,845	80,110	1,06,665
	(b) Other Operating Income	393	477	561	1,349	1,602	2,741
	Total Income from Operations (Net) (a+b)	27,812	28,481	27,782	77,194	81,712	1,09,406
2	Other Income	55	234	114	375	247	414
3	Total Income (1+2)	27,867	28,715	27,896	77,569	81,959	1,09,820
4	Expenses						
	(a) Cost of materials consumed	7,020	7,551	6,766	20,628	21,729	30,278
	(b) Purchases of stock-in-trade	1,779	1,499	1,649	5,063	6,338	8,039
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	250	975	1,413	494	374	(156)
	(d) Employee Benefits Expense	5,790	5,537	5,507	16,957	15,922	21,605
	(e) Research & Development Expense	1,439	1,175	1,382	3,971	3,785	5,171
	(f) Other Expenses	7,213	7,651	7,149	21,538	21,159	28,807
	(g) Finance Costs	212	697	256	1,518	771	616
	(h) Depreciation and Amortisation Expense	1,730	1,721	1,438	5,138	4,786	6,327
	Total Expenses	25,433	26,806	25,560	75,307	74,864	1,00,687
5	Profit/(Loss) before Tax (3-4)	2,434	1,909	2,336	2,262	7,095	9,133
6	Tax Expenses - Current	464	-	498	464	1,514	1,962
	- Deferred	(296)	(67)	79	(271)	(370)	(574)
	Total Tax Expenses	168	(67)	577	193	1,144	1,388
7	Profit/(Loss) for the period (5-6)	2,266	1,976	1,759	2,069	5,951	7,745
8	Other Comprehensive Income						
a	i) Items that will not be reclassified to profit and loss	(4)	(5)	(5)	(14)	(15)	20
	ii) Income tax on relating to this item	2	2	2	5	5	(7)
b	i) Items that may be reclassified to profit or loss	-	-	-	-	-	-
	Total Other Comprehensive Income	(2)	(3)	(3)	(9)	(10)	13
	Total Comprehensive income for the year	2,264	1,973	1,756	2,060	5,941	7,758
9	Paid up Equity Share Capital (Face value ₹ 2/- each)	1,843	1,843	1,843	1,843	1,843	1,843
10	Other Equity	-	-	-	-	-	63,345
11	Earnings per share (of ₹ 2/- each)						
	(a) Basic- in ₹	2.46	2.14	1.91	2.25	6.46	8.40
	(b) Diluted- in ₹	2.46	2.14	1.91	2.25	6.46	8.40

Notes :

1 Above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 25th January, 2018.

2 The company has only one primary reportable segment of activity, namely, Pharmaceuticals.

Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows:

(₹ In Lakhs)

Net Sales and Income from Operations	Quarter ended 31.12.2017 (Unaudited)	Quarter ended 30.09.2017 (Unaudited)	Quarter ended 31.12.2016 (Unaudited)	Nine months ended 31.12.2017 (Unaudited)	Nine months ended 31.12.2016 (Unaudited)	Year ended 31.03.2017 (Audited)
India	16,347	19,749	15,169	47,118	48,074	61,597
Outside India	11,072	8,255	12,052	28,727	32,036	45,068
Total	27,419	28,004	27,221	75,845	80,110	1,06,665

3 The statutory auditors of the company have carried out limited review of the financial results for the quarter ended 31st December, 2017.

4 The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable.

By Order of the Board
For Indoco Remedies Ltd

sd/-

Suresh G. Kare
Chairman

Place : Mumbai

Date : 25th January, 2018